Latest News

Approach centers on pressure-free messaging and optometric education

Patient enrollment is complete in a phase 3 registrational, or pivotal, trial to evaluate OPGx-LCA5, a gene therapy that is under investigation for treating Leber congenital amaurosis type 5-associated inherited retinal disease.

Two investigational pipeline therapies take aim at the root causes of dry eye disease

Margaret A. Chang, MD, MS, on MK-8748's dual Tie2/VEGF mechanism, what MALBEC's data must show to shift wet AMD care, and where DME and RVO fit next.

Noha Ekdawi, MD, FAAP, explains why pediatric myopia demands individualized, progression-based management—detailing how they sequence spectacle defocus lenses, low-dose atropine, and specialty contacts; drive long-term adherence; and frame lifetime risk for parents without causing alarm.

Wnt pathway modulation, sustained-release TKI delivery, and topical steroid dosing are advancing through phase 3 trials in DME, testing approaches distinct from standard anti-VEGF injections.

Waste, cost, and carbon are converging to reshape how cataract centers choose instruments.

A maternal high-fat diet can negatively affect the retinal structure in mice.

Ahead of his November 10, 2026, start date, the incoming Duke ophthalmology chair shares his vision for research, training, and the integration of AI and data science.

Sight Sciences' newest MIGS device gains FDA clearance for single-pass canaloplasty and trabeculotomy in open-angle glaucoma.

The trial is evaluating the company’s orally administered synthetic cannabinoid, ART27.13

Gene therapies, Tie2 agonism, and new delivery platforms are advancing through phase 3 trials in wet and dry AMD, testing mechanisms distinct from anti-VEGF and complement inhibition.

In this Q&A from EDES 2026 in Milan, Piotr A. Woźniak, MD, PhD, discusses his real-world evidence study on a dry eye lubricating drop, including its effects on tear film stability.